Last $97.40 USD
Change Today -1.76 / -1.77%
Volume 1.5M
NVS On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
Frankfurt
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVS) Snapshot

Open
$97.90
Previous Close
$99.16
Day High
$98.52
Day Low
$97.39
52 Week High
01/20/15 - $102.59
52 Week Low
02/4/14 - $77.90
Market Cap
263.6B
Average Volume 10 Days
3.6M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
03/2/15
P/E TM
--
Dividend
$2.82
Dividend Yield
2.83%
Current Stock Chart for NOVARTIS AG-SPONSORED ADR (NVS)

novartis ag-sponsored adr (NVS) Related Businessweek News

View More BusinessWeek News

novartis ag-sponsored adr (NVS) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

130,000 Employees
Last Reported Date: 01/27/15
Founded in 1895

novartis ag-sponsored adr (NVS) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.6.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: SFr.3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: SFr.3.9M
Compensation as of Fiscal Year 2014.

novartis ag-sponsored adr (NVS) Key Developments

European Commission Approves Both GSK's Acquisition of Novartis' Vaccines Business and Consumer Healthcare Joint Venture Between GSK and Novartis

The European Commission has cleared under the EU Merger Regulation both the proposed acquisition of the vaccines business of Novartis' by GlaxoSmithKline, as well as the proposed creation of a new entity combining the consumer health activities of GSK and Novartis. The decision is conditional upon the divestiture of assets in the vaccines and consumer health businesses. The Commission had concerns that the transaction would have eliminated an important competitor to GSK for the supply of several vaccines and consumer health products, which might lead to price increases for European consumers. The commitments address these concerns. As a result of the transaction: GSK will acquire Novartis' global human vaccines business, except the influenza vaccines business; and GSK and Novartis will combine their global consumer health business in a new entity, which will be controlled by GSK. This transaction is part of a 3-part inter-conditional deal between the two companies: in a separately notified case (M.7275) Novartis plans to acquire part of GSK's oncology business portfolio. In a separate decision taken, the Commission has also approved that part of the deal.

Novartis AG Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Proposes Earnings Guidance for the Fiscal 2015; Proposes Increased Dividend Payment for 2014; Proposes Amendment to its Articles of Incorporation; Reports Impairment Charges for the Fourth Quarter Ended December 31, 2014

Novartis AG announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported fourth-quarter net profit slipped 26% to USD 1.4 billion, dented by negative currency effects and a pre-tax impairment charge of USD 1.1 billion on the pending sale of the influenza vaccines business against net income of USD 1,999 million a year ago. Operating profit plummeted 49% to USD 1.2 billion against USD 2,278 million a year ago. Net sales were USD 14.63 billion against USD 14.93 billion a year ago. Core operating income was USD 3.32 billion against USD 3.29 billion a year ago. Core net income was USD 2.9 billion against USD 2.89 billion a year ago. Core net income attributable to shareholders was USD 2.92 billion against USD 2.86 billion a year ago. Core EPS was USD 1.21 against USD 1.18 a year ago. Group operating income decreased 49% mainly due to an exceptional pre-tax impairment charge. Group net income was down 26%, mainly due to lower operating income. EPS was down slightly less than net income due to lower average outstanding shares and lower minority interest. Core EPS was growing ahead of core net income mainly due to lower average outstanding shares and lower minority interest. Net sales from continuing operations were USD 13.13 billion against USD 13.4 billion a year ago. Operating income from continuing operations was USD 2.35 billion against USD 2.33 billion a year ago. Core operating income from continuing operations was USD 3.23 billion against USD 3.29 billion a year ago. Cash flow from group total operating activities in the fourth quarter amounted to USD 5.2 billion compared to USD 4.5 billion in the prior-year period. The increase was due to higher hedging gains and lower net working capital as well as lower payments out of provisions. Of the group total, continuing operations contributed USD 4.7 billion compared to USD 4.0 billion in the prior-year period. Income before taxes from continuing operations was USD 2.756 billion against USD 2.283 billion a year ago. Net income from continuing operations was USD 2.448 billion against USD 2.015 billion a year ago. Total net income attributable to shareholders of the company was USD 1.49 billion against USD 2.03 billion a year ago. Diluted earnings per share from continuing operations were USD 1.00 against USD 0.81 a year ago. Diluted earnings per share were USD 0.61 against USD 0.82 a year ago. Purchase of property, plant & equipment was USD 830 million against USD 1,048 million a year ago. Core income before taxes was USD 3.36 billion against USD 3.29 billion a year ago. Free cash flow was USD 4.4 billion. Net sales were up 4%, and core operating income was up 9%, driven by the sales performance and the continued impact of productivity programs. The increase in free cash flow was driven by strong operating performance, including exceptional gains from Novartis Venture Fund. For the year, the company reported full-year net profit in 2014 jumped by 12% to USD 10.3 billion against USD 9.14 billion a year ago. Operating profit in the full year grew by 1% to USD 10.7 billion against USD 10.67 billion a year ago. Net sales were USD 58 billion against USD 57.36 billion a year ago. Core operating income was USD 14.62 billion against USD 14.19 billion a year ago. Core net income was USD 12.76 billion against USD 12.35 billion a year ago. Core net income attributable to shareholders was USD 12.68 billion against USD 12.23 billion a year ago. Core EPS was USD 5.23 against USD 5.01 a year ago. As of December 31, 2014, the net debt stood at USD 6.5 billion compared to USD 8.8 billion at December 31, 2013. Net sales from continuing operations were USD 52.18 billion against USD 51.87 billion a year ago. Operating income from continuing operations was USD 11.09 billion against USD 10.98 billion a year ago. Core operating income from continuing operations was USD 14.47 billion against USD 14.21 billion a year ago. Cash flows from operating activities from continuing operations were USD 13.898 billion against USD 12.617 billion a year ago. Cash flow from group total operating activities increased to USD 13.9 billion from USD 13.2 billion in 2013, an increase of USD 0.7 billion. This was primarily due to higher operating income adjusted for non-cash items, despite negative currency effects, and increased hedging gains, partially offset by payments for legal settlements and restructuring. Net sales to third parties from continuing operations were USD 52.18 billion against USD 51.87 billion a year ago. Net sales from continuing operations were USD 52.42 billion against USD 52.090 billion a year ago. Income before taxes from continuing operations was USD 12.272 billion against USD 10.807 billion a year ago. Net income from continuing operations was USD 10.727 billion against USD 9.309 billion a year ago. Total net income attributable to shareholders of the company was USD 10.21 billion against USD 9.17 billion a year ago. Diluted earnings per share from continuing operations were USD 4.31 against USD 3.70 a year ago. Diluted earnings per share were USD 4.13 against USD 3.70 a year ago. Purchase of property, plant & equipment was USD 2.624 billion against USD 2.903 billion a year ago. Core income before taxes was USD 14.83 billion against USD 14.34 billion a year ago. Free cash flow was USD 10.8 billion. Net income improved substantially by 19% in constant currencies in the full year, benefiting from the exceptional gain from the sale of its 22% Idenix stake to Merck. Net debt decreased from USD 8.8 billion at the end of 2013 to USD 6.5 billion at the end of this year of 2014, this was mainly due to its strong free cash flow of USD 10.8 billion as well as proceeds from divestments. For the year 2015, the company expects group net sales in 2015 to grow in the mid-single digit percentage range at constant exchange rates. Group core operating income is projected to grow at a high-single digit percentage rate. Group net sales in 2015 are expected to grow mid-single digit (cc), after absorbing the impact of generic competition, which is expected to be as much as USD 2.5 billion compared to USD 2.4 billion in 2014. The board proposes a dividend payment of CHF 2.60 per share for 2014, up 6% from CHF 2.45 per share in 2013, representing the 18th consecutive dividend increase since the creation of Novartis in December 1996. Shareholders will vote on this proposal at the 2015 Annual General Meeting (AGM) scheduled for February 27, 2015. The board proposes to amend the articles of incorporation of the company to fulfill the requirements of both the Swiss Federal Ordinance Against Excessive Compensation in Public Corporations (OAEC) and current best corporate governance and compensation practices. The company reported total impairment charges of USD 1,361 million for the fourth quarter of 2014 against USD 111 million a year ago.

Novartis Eyes Acquisitions

Novartis AG (SWX:NOVN) is looking for acquisition opportunities. Joe Jimene, Chief Executive Officer of Novartis, said, “we'll be looking for bolt-on (ph) acquisitions, somewhere in the $2 to $5 billion range that can help us strengthen the pipelines of those divisions.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $97.40 USD -1.76

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $104.83 USD +0.65
Johnson & Johnson $100.14 USD -2.24
Pfizer Inc $31.25 USD -0.58
Roche Holding AG SFr.248.60 CHF -4.10
Sanofi €82.00 EUR -0.26
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 22.7x
Price/Sales 4.4x
Price/Book 3.3x
Price/Cash Flow 25.9x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.